ArticleAnnals of the rheumatic diseases2022

Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng

Dimitrios A Pappas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.